In general, I prefer simple investment ideas over more complicated ones. Gulf Island Fabrication (GIFI) fits the bill; the company is currently trading at a 30% discount to its book value and based on recent asset sales I think the company should close that gap in the coming year. While the company's earnings have been poor for multiple years, their last two quarters have been operationally cashflow neutral and recent project commitments have given them a healthy backlog going into 2019. I don't expect GIFI to wow investors with their earnings anytime soon, but if management can show the market that operations have stabilized by the end of 2019, I think the company will trade close to book value and provide an investor with 30% upside.
Company InformationGIFI has three primary sources of revenue: building small-scale marine vessels (think tugboats, ferries, etc) for the US Navy and state governments, fabricating steel structures for offshore drilling and other various marine projects, and providing maintenance and engineering support services for offshore oil platforms. Of the three divisions, only the services division is currently profitable, with the ship building and fabrication divisions both having negative gross margins in 2018. The fabrication division has been hit particularly hard of late, with a slowdown in the offshore drilling market leading to under-utilization of their production facilities and tariffs on imported steel cutting into their margins. Fabrication revenues fell almost 35% in 2018, though this revenue loss was offset by an almost equally-sized improvement in services revenue. The shipyard division grew revenues substantially over the year, with an 83% growth in sales coming primarily from a new project to construct ten harbor tugboats for the US Navy. Despite resulting in a jump in revenue, the tugboat project has been marred by problems with the ships' piping systems, leading to increased production costs and forcing the company's CEO to admit on the latest conference call that the project will not result in any profit for GIFI. A small silver lining over the last two quarters has been positive cash flow from operations. Despite tallying a net loss of over $15 million through Q3 and Q4 of 2018, the company was able to produce over $6 million in cash from their operations over that time frame.
Top 5 Value Stocks To Watch For 2019: SPDR S&P MidCap 400 ETF (MDY)
Advisors' Opinion:- [By Joseph Griffin]
Round Table Services LLC increased its position in SPDR S&P MidCap 400 ETF Trust (NYSEARCA:MDY) by 19.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,239 shares of the exchange traded fund’s stock after buying an additional 1,642 shares during the period. SPDR S&P MidCap 400 ETF Trust comprises approximately 1.2% of Round Table Services LLC’s holdings, making the stock its 20th largest position. Round Table Services LLC’s holdings in SPDR S&P MidCap 400 ETF Trust were worth $3,635,000 at the end of the most recent quarter.
- [By Max Byerly]
Curbstone Financial Management Corp reduced its holdings in SPDR S&P MidCap 400 ETF (NYSEARCA:MDY) by 1.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,360 shares of the exchange traded fund’s stock after selling 800 shares during the quarter. SPDR S&P MidCap 400 ETF makes up 4.1% of Curbstone Financial Management Corp’s portfolio, making the stock its 2nd biggest holding. Curbstone Financial Management Corp owned approximately 0.07% of SPDR S&P MidCap 400 ETF worth $14,684,000 as of its most recent SEC filing.
- [By ]
Yet when it comes to investing, reward often comes from being willing to take on risk. Over the past 10 years, investors who've been willing to look at smaller companies have seen much stronger returns than those who've stuck with the tried-and-true big names that are more familiar to them. When you look at exchange-traded funds tracking indexes composed of companies of different sizes — SPDR S&P 500 (NYSEMKT: SPY) for large companies, SPDR S&P Midcap 400 (NYSEMKT: MDY) for midsize companies and SPDR S&P SmallCap 600 (NYSEMKT: SLY) for small companies — you can put a number on just how much better smaller stocks have done:
Top 5 Value Stocks To Watch For 2019: Grifols, S.A.(GRFS)
Advisors' Opinion:- [By Shane Hupp]
Grifols (NASDAQ:GRFS) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
- [By Max Byerly]
Financial Gravity Companies Inc. raised its stake in shares of Grifols (NASDAQ:GRFS) by 264.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 13,862 shares of the biotechnology company’s stock after purchasing an additional 10,054 shares during the quarter. Financial Gravity Companies Inc.’s holdings in Grifols were worth $282,000 as of its most recent filing with the SEC.
Top 5 Value Stocks To Watch For 2019: Collegium Pharmaceutical, Inc.(COLL)
Advisors' Opinion:- [By Motley Fool Transcribers]
Collegium Pharmaceutical Inc (NASDAQ:COLL)Q4 2018 Earnings Conference CallFeb. 27, 2019, 4:30 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Max Byerly]
Collegium Pharmaceutical Inc (NASDAQ:COLL) shares were up 6.5% during trading on Friday . The stock traded as high as $15.15 and last traded at $14.79. Approximately 511,962 shares traded hands during trading, an increase of 20% from the average daily volume of 425,396 shares. The stock had previously closed at $13.89.
- [By Joseph Griffin]
State Board of Administration of Florida Retirement System acquired a new stake in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 10,174 shares of the specialty pharmaceutical company’s stock, valued at approximately $260,000.
- [By Todd Campbell]
Depomed is in the middle of a restructuring of its business that includes out-licensing its lead drug, Nucynta. In December, Collegium (NASDAQ:COLL) cut a licensing deal for Nucynta that guarantees Depomed $135 million in annual royalties, paid quarterly in arrears, for four years. If sales exceed $233 million per year, then Collegium Pharmaceutical will also pay Depomed a double-digit royalty on top of the minimum license fee. After four years, Depomed will receive double-digit royalties on all net Nucynta sales.
- [By Logan Wallace]
Collegium Pharmaceutical (NASDAQ:COLL) – Piper Jaffray lowered their FY2021 EPS estimates for shares of Collegium Pharmaceutical in a note issued to investors on Wednesday, May 9th. Piper Jaffray analyst D. Amsellem now forecasts that the specialty pharmaceutical company will post earnings per share of $2.06 for the year, down from their previous forecast of $2.32. Piper Jaffray has a “Buy” rating and a $33.00 price target on the stock.
Top 5 Value Stocks To Watch For 2019: Xilinx, Inc.(XLNX)
Advisors' Opinion:- [By Joseph Griffin]
Get a free copy of the Zacks research report on Xilinx (XLNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Earnest Partners LLC increased its stake in Xilinx, Inc. (NASDAQ:XLNX) by 0.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 845,144 shares of the programmable devices maker’s stock after purchasing an additional 7,393 shares during the period. Earnest Partners LLC owned approximately 0.33% of Xilinx worth $61,053,000 as of its most recent SEC filing.
- [By Harsh Chauhan]
Investors can take advantage of this opportunity through Xilinx (NASDAQ:XLNX), a pure-play FPGA company, or through Intel (NASDAQ:INTC), a chip behemoth with diversified interests, but one of them trumps the other.
- [By Lee Jackson]
This top chip company blew away earnings estimates and the shares soared higher. Xilinx Inc. (NASDAQ: XLNX) is a leading fabless supplier of high-density programmable logic devices, which are standard integrated circuits that offer significant advantages over custom logic chips, such as application-specific integrated circuits. They are used extensively in key end markets such as communications.
Top 5 Value Stocks To Watch For 2019: iShares Nasdaq Biotechnology Index Fund(IBB)
Advisors' Opinion:- [By Benzinga News Desk]
After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory decisions: Link
- [By ]
The SPDR S&P Biotech ETF (NYSE:XBI) – a good measure of small-cap biotech stocks – gained almost 6% yesterday. Meanwhile, the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) jumped almost 4%. The biotech buying frenzy helped lift the Nasdaq Composite to a gain of almost 1% in Monday's session.
- [By Joseph Griffin]
Exencial Wealth Advisors LLC increased its stake in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 21.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,978 shares of the financial services provider’s stock after purchasing an additional 711 shares during the period. Exencial Wealth Advisors LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $384,000 as of its most recent SEC filing.
- [By Logan Wallace]
Private Capital Advisors Inc. lowered its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 97.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,811 shares of the financial services provider’s stock after selling 77,946 shares during the period. Private Capital Advisors Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $604,000 as of its most recent SEC filing.
- [By Joseph Griffin]
LPL Financial LLC grew its holdings in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 11.9% during the first quarter, HoldingsChannel reports. The firm owned 512,225 shares of the financial services provider’s stock after purchasing an additional 54,371 shares during the period. LPL Financial LLC’s holdings in iShares NASDAQ Biotechnology Index were worth $54,675,000 as of its most recent SEC filing.
No comments:
Post a Comment